journal
https://read.qxmd.com/read/38776393/changes-in-categorization-or-nomenclature-within-neuroendocrine-tumours
#1
REVIEW
Giulia Vocino Trucco, Marco Volante
The 5th Edition of WHO classification of neuroendocrine neoplasms is built to achieve a uniform terminology and to define a similar diagnostic scheme across different anatomical locations. At variance with the 4th edition, a chapter discussing neuroendocrine neoplasms in non-neuroendocrine organs has been introduced, that proposes a binary system for classification segregating well differentiated neoplasms, termed neuroendocrine tumors (NET), and poorly differentiated neoplasms, termed neuroendocrine carcinomas (NEC)...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38768280/the-role-of-the-tumor-microenvironment-in-papillary-thyroid-microcarcinoma-nodal-metastasis
#2
JOURNAL ARTICLE
Mijin Kim, Chae Hwa Kwon, Bo Hyun Kim
The genetic alterations currently identified in papillary thyroid microcarcinomas (PTMCs) are insufficient for distinguishing tumors with aggressive features. We aimed to identify candidate markers associated with lateral lymph node metastasis (LLNM, N1b disease) in patients with PTMC using transcriptomic analysis. RNA sequencing was performed on 26 matched tumor and normal thyroid tissue samples (N0, n = 14; N1b, n = 12), followed by functional enrichment analyses of differentially expressed genes (DEGs). EcoTyper was used to explore the distinct tumor microenvironment (TME)...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38767322/epas-1-related-pheochromocytoma-paraganglioma-how-common-and-how-aggressive
#3
JOURNAL ARTICLE
Ali S Alzahrani, Meshael Alswailem, Alexandre Buffet, Balgees Alghamdi, Lulu Alobaid, Osamah Alsagheir, Hindi Al-Hindi, Karel Pacak
In 2012, somatic EPAS1 pathogenic variants were found to cause a triad of pheochromocytoma/paragangliomas (PPGL), polycythemia and somatostatinoma. Since then, a limited number of studies on this subject have been reported and data on the long-term outcome of metastatic disease are not available on this rare syndrome. We comprehensively reviewed EPAS1-related PPGL and describe an unusual patient who has been living with an EPAS1-related metastatic PPGL for 47 years. The results of this work show that EPAS1 pathogenic variants are rare, more in females and patients without pathogenic variants in other PPGL susceptibility genes...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38758683/advancements-and-challenges-in-pheochromocytoma-and-paraganglioma-research-a-collection-of-insights
#4
REVIEW
Judith Favier, Karel Pacak, Roderick J Clifton-Bligh
The endocrine community has witnessed significant advances in understanding and management of pheochromocytoma and paraganglioma, thanks to continuous and relentless efforts of healthcare professionals and researchers worldwide. The 6th International Symposium on Pheochromocytoma (ISP) held in Prague, Czech Republic in September 2022 brought together experts from various disciplines underscoring the importance of unity in pursuit of clinical and basic research progress in these challenging endocrine tumors (Pacak and Clifton-Bligh 2023)...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38753300/genotype-specific-development-of-men-2-constituent-components-in-683-ret-carriers
#5
JOURNAL ARTICLE
Andreas Machens, Kerstin Lorenz, Frank Weber, Tim Brandenburg, Dagmar Führer-Sakel, Henning Dralle
The age-specific development of the 3 constituent components of multiple endocrine neoplasia type 2 (MEN 2) is incompletely characterized for many of the >30 causative rearranged during transfection (RET) mutations, which this genetic association study aimed to specify. Included in the study were 683 carriers of heterogeneous RET germline mutations: 53 carriers with 1 highest-risk mutation (codon 918); 240 carriers with 8 different high-risk mutations (codon 634); 176 carriers with 16 different intermediate-risk mutations (codon 609, 611, 618, 620 or 630); and 214 carriers with 6 different low-risk mutations (codon 768, 790, 804 or 891)...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38713182/pegvisomant-or-pasirotide-in-prl-and-gh-co-secreting-vs-gh-secreting-pit-nets
#6
JOURNAL ARTICLE
Marta Araujo-Castro, Betina Biagetti, Edelmiro Menedez-Torre, Iría Novoa-Testa, Fernando Cordido, Eider Pascual-Corrales, Víctor Rodríguez Berrocal, Fernando Guerrero-Pérez, Almudena Vicente, Juan Carlos Percovich Hualpa, Rogelio Garcia Centeno, Laura González Fernández, María Dolores Ollero García, Ana Irigaray Echarri, María Dolores Moure Rodríguez, Cristina Novo-Rodríguez, María Calatayud, Rocío Villar, Ignacio Bernabéu, Cristina Alvarez-Escola, Pamela Benítez Valderrama, Carmen Tenorio, Pablo Abellán Galiana, Eva Venegas, Inmaculada González-Molero, Pedro Iglesias, Concepción Blanco-Carrera, Fernando Vidal-Ostos De Lara, Paz de Miguel Novoa, Elena López Mezquita, Felicia Alexandra Hanzu, Iban Aldecoa, Silvia Aznar, Cristina Lamas, Anna Aulinas, Anna Queralt Asla, Paola Gracia Gimeno, José María Recio Córdova, Mariola Aviles, Diego Asensio-Wandosel, Miguel Sampedro-Núñez, Rosa Camara, Miguel Paja Fano, Ignacio Ruz-Caracuel, Carmen Fajardo, Mónica Marazuela, Manel Puig-Domingo
AIM: To evaluate the efficacy of second-line therapies in patients with acromegaly caused by a growth hormone (GH) and prolactin (PRL) co-secreting pituitary neuroendocrine tumor (GH/PRL-Pit-NET) and compare to those caused by a GH-Pit-NET. METHODS: A multicenter retrospective study of patients with acromegaly on treatment with pasireotide or pegvisomant. Patients were classified in two groups: GH/PRL-Pit-NETs when evidence of hyperprolactinemia and immunohistochemistry (IHC) for GH and PRL was positive or if PRL were >200 ng/dL regardless of the PRL-IHC; and GH-Pit-NETs when the previously mentioned criteria were not met...
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38688318/importance-of-3%C3%AE-hydroxysteroid-dehydrogenases-and-their-clinical-use-in-prostate-cancer
#7
REVIEW
Masaki Shiota, Satoshi Endo, Shigehiro Tsukahara, Tokiyosh Tanegashima, Satoshi Kobayashi, Takashi Matsumoto, Masatoshi Eto
Androgen receptor signaling is crucial for the development of treatment resistance in prostate cancer. Among steroidogenic enzymes, 3β-hydroxysteroid dehydrogenases (3βHSDs) play critical roles in extragonadal androgen synthesis, especially 3βHSD1. Increased expression of 3βHSDs is observed in castration-resistant prostate cancer tumors compared with primary prostate tumors, indicating their involvement in castration resistance. Recent studies link 3βHSD1 to resistance to androgen receptor signaling inhibitors...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38657661/patient-reported-burden-associated-with-pheochromocytoma-paraganglioma-diagnosis
#8
JOURNAL ARTICLE
Katherine Wolf, Linda Rose-Krasnor, Stephanie Alband, Jacques W M Lenders, Lauren Fishbein
Pheochromocytoma and paragangliomas (PPGLs) originate from the chromaffin cells of the adrenal medulla or neural crest progenitors outside the adrenal gland, respectively. The estimated annual incidence of PPGL is between 2.0-8.0/million adults. Minimal data exist on the impact of PPGL from the patient perspective. Therefore, a survey was adapted from a previously published study on gastroenteropancreatic neuroendocrine tumors to explore the voice of patients with PPGL and learn ways to improved clinical care while understanding the current gaps to direct future research...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38657656/a-zebrafish-xenotransplant-model-of-anaplastic-thyroid-cancer-to-study-the-tumor-microenvironment-and-innate-immune-cell-interactions-in-vivo
#9
JOURNAL ARTICLE
Cassia Michael, Juliana Moreira Mendonça-Gomes, Clinton Walton DePaolo, Antonio Di Cristofano, Sofia De Oliveira
Anaplastic thyroid cancer (ATC) is of the most aggressive thyroid cancer. While ATC is rare it accounts for a disproportionately high number of thyroid cancer-related deaths. Here we developed an ATC xenotransplant model in zebrafish larvae, where we can study tumorigenesis and therapeutic response in vivo. Using both mouse (T4888M) and human (C643) derived fluorescently labeled ATC cell lines we show these cell lines display different engraftment rates, mass volume, proliferation, cell death, angiogenic potential and neutrophil and macrophage recruitment and infiltration...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38642579/neuropilin-2-and-soluble-neuropilin-2-in-neuroendocrine-neoplasms
#10
JOURNAL ARTICLE
Laura Gerard, Céline Patte, Laurence Chardon, Valerie Hervieu, Léa Payen, Marion Allio, Claire Marx, Hugo Clermidy, Alice Durand, Patrick Mehlen, Julien Bollard, Gilles Poncet, Colette Roche, Benjamin Gibert, Thomas Walter
Neuropilin-2 (NRP2), a transmembrane non-tyrosine kinase receptor, has been described as a potential critical player in the tumourigenesis of several solid cancers, and particularly in neuroendocrine neoplasms (NEN). A soluble form of NRP2 (sNRP2) has been previously described and corresponds to a truncated splice isoform. Its prognostic value has never been studied in NEN. NRP2 expression was studied by immunochemistry on tissue microarrays (n=437) and on circulating tumour cells (CTC, n=5 patients with neuroendocrine carcinoma, NEC)...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38614127/gpnmb-promotes-tumor-growth-and-is-a-biomarker-for-lymphangioleiomyomatosis
#11
JOURNAL ARTICLE
Erin Gibbons, Manisha Taya, Huixing Wu, Samia H Lopa, Joel Moss, Elizabeth P Henske, Francis X Mccormack, Stephen R Hammes
Lymphangioleiomyomatosis (LAM) is a rare, progressive cystic lung disease affecting almost exclusively female-sexed individuals. The cysts represent regions of lung destruction caused by smooth muscle tumors containing mutations in one of the two tuberous sclerosis (TSC) genes. mTORC1 inhibition slows but does not stop LAM advancement. Furthermore, monitoring disease progression is hindered by insufficient biomarkers. Therefore, new treatment options and biomarkers are needed. LAM cells express melanocytic markers, including glycoprotein non-metastatic melanoma protein B (GPNMB)...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38552306/genetic-disorders-and-insulinoma-glucagonoma
#12
REVIEW
Francesca Marini, Francesca Giusti, Maria Luisa Brandi
Insulinoma and glucagonoma are two rare functioning neoplasms of the neuroendocrine cells of the pancreas, respectively characterized by an uncontrolled over-secretion of insulin or glucagon, responsible for the development of the hypoglycemic syndrome and the glucagonoma syndrome. They prevalently arise as sporadic tumors; only about 10% of cases develop in the context of rare inherited tumor syndromes, such as Multiple Endocrine Neoplasia Type 1 (MEN1), Neurofibromatosis type 1 (NF1), and Tuberous Sclerosis Complex (TSC), being the result of an autosomal dominant germline heterozygous loss-of-function mutation in a tumor suppressor gene...
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38470169/rab5a-polarizes-macrophage-and-promotes-breast-cancer
#13
JOURNAL ARTICLE
Lei Qiao, Chao Dong, Wenlei Jia, Gang Sun
Breast cancer is the leading cause of cancer-related deaths in females, and triple-negative breast cancer (TNBC) is characterized as one of the main subtypes of breast cancer, with poor prognosis and limited treatments. Investigating the molecular basis or discovering relevant oncogenes will greatly help to develop effective targeted therapies. In this study, we ascertained that RAB5A depletion in TNBC cells suppresses the secretion of exosomes and blocks the polarization of macrophages toward an M2 phenotype...
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38457246/hspb1-promotes-tumor-invasion-by-inducing-angiogenesis-in-pitnets
#14
JOURNAL ARTICLE
Bin Li, Sida Zhao, Yiyuan Chen, Hua Gao, Weiyan Xie, Hongyun Wang, Peng Zhao, Chuzhong Li, Yazhuo Zhang
The clinical diagnosis and treatment of Pituitary neuroendocrine tumors (PitNETs) that invade the cavernous sinus are fraught with difficulties and challenges. Exploring the biological characteristics involved in the occurrence and development of PitNETs that invade the cavernous sinus will help to elucidate the mechanism of cavernous sinus invasion. There are differences between intrasellar tumors (IST) and cavernous sinus-invasion tumors (CST) in ultra-microstructure, tumor microenvironment (TME), gene expression, and signaling pathways...
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38442006/letter-to-the-editor-clinical-and-basic-research-implications-of-the-article-igf-1-axis-changes-with-adt-and-docetaxel-in-metastatic-prostate-cancer
#15
LETTER
Isabel Heidegger, Zoran Culig
letter to the editor- no abstract.
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38631379/glucagon-and-insulin-100-years-young
#16
EDITORIAL
Wouter W de Herder, Günter Klöppel
No abstract text is available yet for this article.
May 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38235757/immunotherapy-for-endocrine-tumours-a-clinician-s-perspective
#17
REVIEW
Anna Angelousi, Ploutarchos Tzoulis, Marina Tsoli, Eleftherios Chatzellis, Anna Koumarianou, Gregory Kaltsas
Immunotherapy has revolutionised the treatment of oncological patients, but its application in various endocrine tumours is rather limited and is mainly used when conventional therapies have failed. Immune checkpoint inhibitors (ICIs) have been employed in progressive adrenocortical carcinoma, primarily utilizing the anti-PD-L1 agent pembrolizumab, obtaining overall response rates ranging between 14% and 23%. In contrast, the response rate in phaeochromocytoma/paraganglioma was substantially less at 9%, considering the small number of patients treated...
April 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38174978/growth-hormone-and-radiation-therapy-friend-foe-or-both
#18
REVIEW
Verónica A Bahamondes Lorca, Shiyong Wu
Radiotherapy is one of the major options currently for cancer treatment. Radiotherapy causes cellular damage inducing cell death, which is expected to be selective for tumor cells. However, side effects that alter the surrounding normal tissue are often hard to be avoided. When radiation involves the hypothalamic-pituitary axis, growth hormone deficiency (GHD) is frequently induced, causing developmental and metabolic-related diseases in childhood cancer survivors. Growth hormone (GH) replacement therapy has been used for these patients and has been shown to be safe in general...
March 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38376827/subgroup-analysis-of-steadily-increased-trends-in-medullary-thyroid-carcinoma-incidence-and-mortality-in-the-united-states-2000-2020-a-population-based-retrospective-cohort-study
#19
JOURNAL ARTICLE
Zixia Tao, Xianzhao Deng, Bomin Guo, Zheng Ding, You-Ben Fan
The incidence rate of medullary thyroid carcinoma (MTC) continues to grow, along with its mortality rate in the United States. However, the subgroup trends in medullary thyroid carcinoma have not yet been established. This population-based retrospective cohort study was based on the Surveillance, Epidemiology, and End Results-17/12 registry database. Subgroup analysis was performed through clinicopathological and treatment-related characteristics. Annual average percent change (AAPC) was calculated using joinpoint regression analysis...
February 1, 2024: Endocrine-related Cancer
https://read.qxmd.com/read/38363202/multivariable-model-versus-ajcc-staging-system-cancer-specific-survival-predictions-in-adrenocortical-carcinoma
#20
JOURNAL ARTICLE
Letizia Maria Ippolita Jannello, Simone Morra, Lukas Scheipner, Andrea Baudo, Carolin Siech, Mario de Angelis, Nawar Touma, Zhe Tian, Jordan A Goyal, Stefano Luzzago, Francesco Alessandro Mistretta, Mattia Luca Piccinelli, Fred Saad, Felix K H Chun, Alberto Briganti, Sascha Ahyai, Luca Carmignani, Nicola Longo, Ottavio De Cobelli, Gennaro Musi, Pierre I Karakiewicz
We developed a novel contemporary population-based model for predicting cancer-specific survival (CSS) in adrenocortical carcinoma (ACC) patients and compared it with the established 8th edition of the American Joint Committee on Cancer staging system (AJCC). Within the Surveillance, Epidemiology, and End Results database (2004-2020), we identified 1056 ACC patients. Univariable Cox regression model addressed CSS. Harrell's concordance index (c-index) quantified accuracy after 2000 bootstrap resamples for internal validation...
February 1, 2024: Endocrine-related Cancer
journal
journal
32030
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.